Byetta and Insulin
Links shared publicly online about this topic
Medical News: FDA Okays Byetta Plus Insulin Glargine - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a new indication for the type 2 diabetes drug exenatide (Byetta) as an add-on therapy with insulin glargine, diet, and exercise for adult patients.” View full resource at medpagetoday.com
Most Recently Shared on October 20, 2011 at 6:35 pm By:
FDA okays Byetta plus insulin glargine: http://t.co/SjJfiocG
Eli Lilly and Company - BYETTA® Approved for Use with Basal Insulin in Europe
newsroom.lilly.com — “Eli Lilly and Company - BYETTA® Approved for Use with Basal Insulin in Europe” View full resource at newsroom.lilly.com
Most Recently Shared on March 23, 2012 at 6:43 pm By:
BYETTA® Approved for Use with Basal Insulin in Europe (Lilly) http://t.co/W8GNvepK
Byetta and Lantus Insulin Combo Getting Big Hype - Deserved?
diabetes.about.com — “Byetta and Lantus Insulin Combo Getting Big Hype - Deserved?” View full resource at diabetes.about.com
Most Recently Shared on December 12, 2010 at 4:12 am By:
Byetta and Lantus Insulin Combo Getting Big Hype – Deserved?: A study regarding Byetta (exenatide) combined with... http://bit.ly/g6qEBb
European Commission grants marketing authorization for use of BYETTA with basal insulin
news-medical.net — “Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.” View full resource at news-medical.net
Most Recently Shared on March 23, 2012 at 1:57 pm By:
European Commission grants marketing authorization for use of BYETTA with basal insulin: Amylin Pharmaceuticals,... http://t.co/3EqmxLdM
Supplemental NDA submitted for Byetta for add-on therapy to insulin - MPR
empr.com — “Amylin Pharmaceuticals and Eli Lilly and Company announced that a supplemental New Drug Application (sNDA) has been submitted to the FDA for the expanded use of Byetta (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.” View full resource at empr.com
Most Recently Shared on December 23, 2010 at 6:23 pm By:
MPR News: Supplemental NDA submitted for Byetta for add-on therapy to insulin: Amylin Pharmaceuticals and Eli Li... http://bit.ly/dWyE1i
Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin | Fox Business
foxbusiness.com — “DOW JONES NEWSWIRES” View full resource at foxbusiness.com
Most Recently Shared on March 23, 2012 at 5:07 pm By:
Ann Bartlett Therapist and ePatient
RT @shelleypetersen: Amylin: EU approves #diabetes treatment Byetta with basal insulin http://t.co/COuthHf7 #healthinnovations #pharma...
Expanded approval for Byetta; but also renal warning
theheart.org — “The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.” View full resource at theheart.org
Most Recently Shared on November 3, 2009 at 6:41 pm By:
heartwire: FDA expands exenatide use; warns of renal-failure risk http://bit.ly/O9Drq
BYETTA® Approved for Use with Basal Insulin in Europe -- SAN DIEGO and INDIANAPOLIS, March 23, 2012 /PRNewswire/ --
prnewswire.com — “BYETTA® Approved for Use with Basal Insulin in Europe. Patients in Pivotal Study Achieved Better Glycemic Control Overall and After Meals.” View full resource at prnewswire.com
Most Recently Shared on March 23, 2012 at 2:41 pm By:
Scott Strumello Patient Expert
Byetta Approved for Use with Basal Insulin in Europe http://t.co/qV6xoa2T via @PRNewswire
Actos and Byetta. | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “Actos and Byetta. | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on March 31, 2010 at 1:04 am By:
Actos and Byetta. http://tinyurl.com/yz2htaq - Keyvive
Eli Lilly and Company - Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
investor.lilly.com — “Eli Lilly and Company - Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin” View full resource at investor.lilly.com
Most Recently Shared on December 23, 2010 at 1:29 pm By:
eyeonfda Pharma and Health Lawyer
Lilly and Amylin file sNDA for Byetta seeking expansion of indication http://ow.ly/3tEr9
Amylin And Lilly Seek Expanded Byetta Approval - Drugs.com MedNews
drugs.com — “From Associated Press (December 22, 2010) Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to e” View full resource at drugs.com
Most Recently Shared on December 23, 2010 at 4:07 pm By:
Drugs and Devices OW OW Health
Amylin And Lilly Seek Expanded Byetta Approval: From Associated Press (December 22, 2010) NEW YORK -- Eli... http://bit.ly/f6aBAT #drug
Byetta Approved as Lantus Add-On :: Diabetes Self-Management
diabetesselfmanagement.com — “On October 19, the US Food and Drug Administration (FDA) approved the Type 2 diabetes medicine Byetta (exenatide) as an add-on treatment to Lantus (insulin glargine) in people who have not achieved blood glucose control with Lantus, diet, and exercise alone...” View full resource at diabetesselfmanagement.com
Most Recently Shared on November 4, 2011 at 3:28 pm By:
Diabetes Self-Mgmt Health Site
#diabetes Byetta has been approved by the FDA as an add-on to Lantus: http://t.co/bu1TmT5z
Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated With Byetta Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia - Drugs.com MedNews
drugs.com — “Retrospective Study of Nearly 375,000 Type 2 Diabetes Patients Presented at American Heart Association 2010 Scientific Sessions Amylin Pharmaceuticals, Inc. (Na” View full resource at drugs.com
Most Recently Shared on November 17, 2010 at 6:28 pm By:
Drugs and Devices OW OW Health
Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associa... http://bit.ly/bXIAL9 #drug
Byetta may cut cardiovascular risk for diabetes patients | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “Byetta may cut cardiovascular risk for diabetes patients | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on November 24, 2010 at 3:26 pm By:
Byetta may cut cardiovascular risk for diabetes patients: CHICAGO A Type 2 diabetes drug… http://goo.gl/fb/dxcPv
Amylin, Lilly submit BYETTA sNDA for type 2 diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “Amylin, Lilly submit BYETTA sNDA for type 2 diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on December 28, 2010 at 5:09 pm By:
Amylin, Lilly submit BYETTA sNDA for type 2 diabetes: Amylin Pharmaceuticals, Inc. and Eli… http://goo.gl/fb/Iaot1
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MedPage Today
Daily, peer reviewed medical news for clinicians
-
Jim
Editor of Glycosmedia
-
Diabetes, Type 2
Organizing type 2 diabetes resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
